These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15855426)

  • 1. Arthritis medications and cardiovascular events.
    Guslandi M
    JAMA; 2005 Apr; 293(16):1975-6; author reply 1976-7. PubMed ID: 15855426
    [No Abstract]   [Full Text] [Related]  

  • 2. Arthritis medications and cardiovascular events.
    Pollack S
    JAMA; 2005 Apr; 293(16):1976; author reply 1976-7. PubMed ID: 15855427
    [No Abstract]   [Full Text] [Related]  

  • 3. Arthritis medications and cardiovascular events.
    Lehmann DF
    JAMA; 2005 Apr; 293(16):1976; author reply 1976-7. PubMed ID: 15855428
    [No Abstract]   [Full Text] [Related]  

  • 4. Arthritis medicines and cardiovascular events--"house of coxibs".
    Topol EJ
    JAMA; 2005 Jan; 293(3):366-8. PubMed ID: 15623849
    [No Abstract]   [Full Text] [Related]  

  • 5. [New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)].
    Brune K
    MMW Fortschr Med; 2004 Feb; 146(9):47. PubMed ID: 15352709
    [No Abstract]   [Full Text] [Related]  

  • 6. Painful lessons.
    Nat Rev Drug Discov; 2005 Oct; 4(10):800-3. PubMed ID: 16237842
    [No Abstract]   [Full Text] [Related]  

  • 7. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 8. Coxibs and cardiovascular disease.
    Fitzgerald GA
    N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
    [No Abstract]   [Full Text] [Related]  

  • 9. Under surveillance.
    Nat Biotechnol; 2005 Jan; 23(1):1. PubMed ID: 15637596
    [No Abstract]   [Full Text] [Related]  

  • 10. Vioxx: an unequal partnership between safety and efficacy.
    Lancet; 2004 Oct 9-15; 364(9442):1287-8. PubMed ID: 15474114
    [No Abstract]   [Full Text] [Related]  

  • 11. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM
    N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract]   [Full Text] [Related]  

  • 12. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 13. Raising the safety bar--the FDA's coxib meeting.
    Okie S
    N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
    [No Abstract]   [Full Text] [Related]  

  • 14. COX-2 inhibitors--lessons in drug safety.
    Psaty BM; Furberg CD
    N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
    [No Abstract]   [Full Text] [Related]  

  • 15. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 16. Discontinuation of Vioxx.
    Kim PS; Reicin AS
    Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669
    [No Abstract]   [Full Text] [Related]  

  • 17. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 18. Vioxx, the implosion of Merck, and aftershocks at the FDA.
    Horton R
    Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
    [No Abstract]   [Full Text] [Related]  

  • 19. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse cardiovascular effects of the coxibs.
    Dogné JM; Supuran CT; Pratico D
    J Med Chem; 2005 Apr; 48(7):2251-7. PubMed ID: 15801815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.